`
`ILLUMINA, INC.
`
`Petitioner
`
`v.
`
`THE SCRIPPS RESEARCH INSTITUTE
`
`Patent Owner
`
`Case IPR2016-01619
`
`Patent 6,060,596
`
`PATENT OWNER THE SCRIPPS RESEARCH INSTITUTE
`
`DECLARATION OF DONALD MONTGOMERY, PHD
`
`
`
`1
`
`
`
`
`
`
`
`I, Donald Montgomery, declare as follows:
`
`
`
`1.
`
`I am currently the President of Nanomaterials Discovery Corporation,
`
`aka NDCPower, in Seattle Washington and Cheyenne, Wyoming. I received my
`
`AB degree in chemistry at Grinnell College in 1984, a Ph.D. degree in chemistry
`
`from Caltech in 1990 and was a post-doctoral fellow in physics at The Joint
`
`Institute for Laboratory Astrophysics, a joint institute between the University of
`
`Colorado (Boulder) and the National Institute for Standards and Technology for
`
`three years. I began my industry career as a scientist at Nanogen in San Diego in
`
`1994. I founded a genetic analysis DNA microarray company called CombiMatrix
`
`in 1996 to make oligonucleotides on electrode array solid phases using local
`
`electrochemical reactions. CombiMatrix was founded based on my inventions to
`
`synthesize oligonucleotides and other linear polymers on solid supports, I am not
`
`being compensated for my time spent reviewing documents and preparing this
`
`statement because it is part of my exchanging my efforts for legal work being
`
`performed for NDCPower by counsel for Patent Owner, Jeff Oster. I do not receive
`
`any compensation or consideration depending on the outcome of this proceeding or
`
`a concurrent litigation proceeding involving a TSRI patent.
`
`
`
`2.
`
`I have reviewed (a) Dower et al. patent (Ex. 1008), (b) the Petition; (c)
`
`the Stoltz Declaration (Ex. 1007) paragraphs 14 through 15 regarding a person of
`
`ordinary skill in the art (POSA) in 1992; (d) Stoltz Declaration (Ex. 1007)
`
`
`
`2
`
`
`
`paragraphs 103-122 regarding what Dr. Stoltz alleges a person of ordinary skill in
`
`the art familiar with Dower et al. (such as me) and Needels et al. (Ex. 2008) could
`
`or would have done or have been motivated to do. Based upon my experiences
`
`synthesizing bifunctional molecules and linear polymers at CombiMatrix in the
`
`later 1990’s, I did not believe that switching to a solution based combinatorial
`
`screening (such as the system described in Brenner and Lerner Ex. 2001, which
`
`was published in June 1992) would provide any advantages over Dower/Affymax
`
`with a solid phase screening. Therefore, the speculation by Dr. Stoltz in Ex. 1007
`
`paragraphs 103-122 does not reflect my first-hand experience of doing
`
`combinatorial screening with any preference to solution-based screening.
`
`
`
`3.
`
`I have reviewed the ‘596 patent specification and claims for the
`
`purposes of determining what I think is meant by the term “linker molecule” or the
`
`B component of the A-B-C structure in claim 1. Based on my review of the entire
`
`specification, it is clear to me that the specification distinguishes polymers, such as
`
`oligonucleotides and peptides that are made from multiple repeating units or
`
`“mers,” from its use of the term “molecule.” A molecule is a defined chemical
`
`structure. As a person who was actively working in the field of combinatorial
`
`chemical synthesis in the 1990’s, I did not consider a solid phase bead structure as
`
`a linker molecule.
`
`
`
`3
`
`
`
`
`
`4.
`
`As is shown in Dower (Ex. 1008), Dower/Affymax accomplished
`
`combinatorial screening after a biological assay by using a FACS cell sorter to
`
`segregate beads with bound antibodies. There was no need and no suggestion that
`
`Dower would or should replace its solid phase method with a soluble bifunctional
`
`molecular linker for soluble combinatorial screening.
`
`
`
`5.
`
`The passage in Needels et al. (Ex. 2006) acknowledging the Brenner
`
`and Lerner publication (Ex. 2001) and what it provides in the form of a
`
`bifunctional molecule for soluble combinatorial screening does not indicate, in my
`
`opinion, that it is obvious over the solid phase bead with two polymers attached in
`
`Dower and Needels et al. (Ex. 2006). Because, for example, the assays used for
`
`combinatorial screening for solid phase or for solution are materially different.
`
`
`
`6.
`
`I read the file history of the priority patent application of the ‘596
`
`patent family (Ex. 2003) and found a restriction requirement indicating that the
`
`method to synthesize the bifunctional molecule and the bifunctional molecule
`
`composition were restricted into separately patentable inventions. The applicants
`
`did not fight this restriction requirement.
`
`
`
`7.
`
`I have reviewed Nielson et al. (Ex. 2005) that showed, in my opinion,
`
`that the Nelson linker molecule did not work well because the amino acid addition
`
`was not efficient. Based on these findings, the authors speculated that the reason
`
`was due to steric hindrance.
`
`
`
`4
`
`
`
`
`
`8.
`
`I declare that all statements made herein of my knowledge are true,
`
`and that all statements made on information and belief are believed to be true, and
`
`that these statements were made with the knowledge that willful false statements
`
`and the like so made are punishable by fine or imprisonment, or both, under
`
`Section 1001 of Title 18 of the United States Code.
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`
`
`
`
`
`
`
`Donald Montgomery, Ph.D.
`
`5
`
`
`
`Dated: 21 November 2016